Maris Hartmanis new BioPhausia CEO

The Board of BioPhausia has appointed Maris Hartmanis as the Company's new CEO.
He takes up his position on 9 August, and succeeds Claes Thulin who has decided
to pursue his own entrepreneurial activities after serving eight years as CEO.

Maris Hartmanis will be working in parallel with Claes Thulin during May and
June. Maris Hartmanis is 56 years of age and has many years of experience in
leading positions in companies in the biotechnology, medical technology and
pharmaceutical industries. He was Senior Vice President of Research and
Development at Gambro between 2004 and 2008 and has held positions in Gyros,
Amersham Biosciences, Pharmacia & Upjohn, Pharmacia and KabiGen.

"We are delighted to have recruited a new CEO with such in-depth and extensive
experience in different areas of the Life Science industry," says BioPhausia's
Chairman of the Board Jan Rynning. "We are convinced that Maris has the
expertise and background required to take BioPhausia into the next phase of its
development."

"BioPhausia is a very interesting company and I look forward to helping continue
the successful growth strategy," says Maris Hartmanis. "I am certain that the
pharmaceutical market niche which BioPhausia occupies has excellent scope for
development."



[HUG#1413198]